

### Hybrigenics first half 2014 revenues and cash

- **Total revenues up 5%**
- **Scientific services turnover up 10%**
- **Cash position EUR 7.4 million**

**Paris, 23 July 2014** – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in proteomic and genomic scientific services, today announces its revenues and cash position for the first half of 2014.

Million EUR	1 <sup>st</sup> Half 2013	1 <sup>st</sup> Half 2014	Growth
<b>Turnover from scientific services</b>	<b>1.37</b>	<b>1.51</b>	<b>+10%</b>
Turnover from research collaboration	0.37	0.37	=
<b>Total turnover</b>	<b>1.75</b>	<b>1.88</b>	<b>+8%</b>
Other revenues	0.50	0.47	-8%
<b>Total revenues</b>	<b>2.25</b>	<b>2.35</b>	<b>+5%</b>
<b>Cash position</b> (end of period)	<b>2.11</b>	<b>7.42</b>	<b>+252%</b>

Hybrigenics' turnover from scientific services for H1 2014 increased by 10%, including €0.37 million from the newly acquired genomic services activity (Helixio). The turnover from the drug discovery collaboration with Servier on de-ubiquitinating enzymes and their inhibitors has remained stable (€0.375 million). As a result, Hybrigenics total turnover increased by 8%. Other revenues from non-core activities slightly decreased. Overall, total revenues grew 5% to reach €2.35 million.

Hybrigenics' cash position on June 30<sup>th</sup>, 2014 amounted to €7.4 million compared to €2.5 million on December 31<sup>st</sup>, 2013, and €2.1 million on June 30<sup>th</sup>, 2013. During H1 2014, a total of €7.15 million has been raised: €6.1m through a private placement in March and €1.05 million from earlier drawings on the equity line agreement with the American fund Yorkville Global Advisors. This agreement has been extended up to December 19, 2015 and €5.0 million are still available on this line.

*"Our external growth strategy of 2013 focused on new genomic services and on the German and Swiss territories for proteomic services, has continued to fuel the growth of the services revenues, despite a slowdown of proteomic services in France. Besides, active fund-raising in the first quarter has resulted in the strongest cash position since 2008. This cash will be used to finance the clinical Phase II study of inecalcitol in combination with imatinib (Gleevec®) in chronic myeloid leukemia which has just been authorized by the French drug agency, and possibly another clinical Phase II study of inecalcitol in combination with azacytidine (Vidaza®) or decitabine (Dacogen®) in frail acute myeloid leukemia patients. Meanwhile, Hybrigenics will design and prepare the next step of inecalcitol development in chronic lymphocytic leukemia. The strategic goal is to find the right positioning of inecalcitol in each of these three orphan adult leukemias,"* said Remi Delansorne, Hybrigenics' CEO.

# HYBRIGENICS

## Press Release

### **About Hybrigenics**

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services ([www.hybrigenics-services.com](http://www.hybrigenics-services.com)) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio ([www.helixio.com](http://www.helixio.com)), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing.

Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

\*\*\*

**HYBRIGENICS is listed on the Alternext market of Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



### **Hybrigenics**

Rémi Delansorne  
CEO  
Tel.: +33 (0)1 58 10 38 00  
[investors@hybrigenics.com](mailto:investors@hybrigenics.com)

### **NewCap.**

Financial communication  
Julien Perez / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
[hybrigenics@newcap.fr](mailto:hybrigenics@newcap.fr)